Analyst Price Targets — IMMX
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| August 11, 2026 12:25 pm | — | Morgan Stanley | $19.00 | $10.08 | TheFly | Immix Biopharma price target lowered to $19 from $20 at Morgan Stanley |
| August 10, 2026 10:16 am | Robert Burns | H.C. Wainwright | $25.00 | $9.72 | TheFly | Immix Biopharma price target raised to $25 from $20 at H.C. Wainwright |
| May 22, 2026 2:38 pm | Robert Burns | H.C. Wainwright | $20.00 | $8.92 | TheFly | Immix Biopharma price target raised to $20 from $15 at H.C. Wainwright |
| March 27, 2026 10:12 am | — | H.C. Wainwright | $15.00 | $8.15 | TheFly | Immix Biopharma price target raised to $15 from $12 at H.C. Wainwright |
| February 9, 2026 10:35 am | Graig Suvannavejh | Mizuho Securities | $14.00 | $6.74 | TheFly | Immix Biopharma initiated with an Outperform at Mizuho |
| December 9, 2025 1:26 pm | — | H.C. Wainwright | $12.00 | $6.38 | TheFly | Immix Biopharma price target raised to $12 from $8 at H.C. Wainwright |
| July 1, 2024 6:08 am | Robert Burns | H.C. Wainwright | $7.00 | $1.98 | TheFly | Immix Biopharma initiated with a Buy at H.C. Wainwright |
Latest News for IMMX
Immix Biopharma, Inc. (NASDAQ: IMMX - Get Free Report)'s stock price hit a new 52-week high during mid-day trading on Tuesday. The company traded as high as $13.80 and last traded at $13.61, with a volume of 1414936 shares changing hands. The stock had previously closed at $13.66. Analyst Ratings Changes Several analysts recently commented
NEW YORK, Aug. 13, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Immix Biopharma, Inc. ("Immix" or the "Company") (NASDAQ: IMMX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
NEW YORK, Aug. 11, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Immix Biopharma, Inc. (“Immix” or the “Company”) (NASDAQ: IMMX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
NEW YORK, Aug. 6, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Immix Biopharma, Inc. ("Immix" or the "Company") (NASDAQ: IMMX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
LOS ANGELES--(BUSINESS WIRE)---- $IMMX--IMMX Investors Have Opportunity to Join Immix Biopharma, Inc. Fraud Investigation with SBS Law.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for IMMX.
U.S. House Trading
No House trades found for IMMX.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.